LG Life Sciences to commercialize next-generation influenza vaccine

Published: 2011-03-03 06:58:00

Updated: 2011-03-03 06:58:00

LG Life Sciences (LGLS) on Tuesday announced an agreement with the US based Novavax, Inc. for the commercialization of the latter’s proprietary, recombinant virus-like-particle (VLP) vaccine technology.

Under the agreement, LGLS receives an exclusive license to manufacture, develop and commerc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK